Myocardial InfarctionCAN-NSTEMINCT06702436
Invasive vs. Conservative Management in Cancer Patients With Non-ST Elevation MI (CAN-NSTEMI)"
An observational study of Myocardial Infarction, run by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
This retrospective study investigates the impact of invasive versus conservative management strategies in cancer patients presenting with non-ST elevation myocardial infarction (non-ST MI). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Myocardial Infarction
- What is being tested?
- Observational Study
- How many people
- 12,500 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jun 2024to 1 Apr 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population will include adult patients aged 18 and older, diagnosed with cancer and hospitalized for non-ST elevation myocardial infarction (NSTEMI). Both males and females with various cancer types will be eligible, and the study will focus on those receiving either invasive or conservative treatment for NSTEMI. Patients with severe comorbidities, such as end-stage diseases or missing critical data, will be excluded. The study aims to assess the impact of invasive versus conservative treatment strategies on mortality, re-hospitalization, and cardiovascular events in this cohort, which is often underrepresented in clinical trials. This population will help understand optimal treatment approaches for cancer patients with NSTEMI.
Who may be able to join
- Age: Patients aged 18 years and older.
- Diagnosis: Patients with a confirmed cancer diagnosis.
- Acute Condition: Patients diagnosed with non-ST elevation myocardial infarction (non-ST MI).
- Treatment: Patients who received either invasive treatment (including coronary angiography and revascularization) or conservative (pharmacological) treatment for non-ST MI.
- Consent: Patients who have provided informed consent or are part of a retrospective study where consent is waived.
Who cannot join
- Age: Patients younger than 18 years.
- Non-cancer diagnoses: Patients without a cancer diagnosis.
- ST-Elevation Myocardial Infarction: Patients with ST elevation myocardial infarction (STEMI) instead of non-ST elevation myocardial infarction (NSTEMI).
- Pre-existing severe comorbidities: Patients with severe or terminal comorbidities (e.g., end-stage liver disease, end-stage renal disease, or severe cognitive impairment) that would confound the outcomes.
- Incomplete medical records: Patients with missing data on relevant clinical variables (e.g., GRACE score, treatment received, or mortality data).
- Pregnancy: Pregnant patients, as their conditions may complicate the interpretation of results.
- Inability to provide informed consent: Patients unable to provide informed consent (if applicable).
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Ankara Oncology Training and Research Hospital
Ankara, Ankara, 06200
About this study
Official title: Impact of Treatment Approaches on Mortality in Cancer Patients With Non-ST Elevation Myocardial Infarction: Invasive vs. Conservative Strategies
This retrospective study investigates the impact of invasive versus conservative management strategies in cancer patients presenting with non-ST elevation myocardial infarction (non-ST MI). Patients aged 18 and older, who were treated for non-ST MI in a hospital setting and had a confirmed cancer diagnosis, are included. The primary outcome is hospital mortality, assessed using GRACE scores to evaluate mortality risk. Patients are grouped based on their received interventions-either invasive (including coronary angiography and revascularization) or pharmacological treatment. Risk factors contributing to mortality, such as cancer type, metastasis presence, comorbidities, and laboratory findings, will also be analyzed to better understand the interplay of oncologic and cardiovascular conditions in this population.
- Conditions
- Myocardial Infarction
- Being tested
- Observational Study
- Keywords
- Non-ST Elevated Myocardial Infarction, Malignancy, Mortality
- Medical subject headings
- Myocardial Infarction, Non-ST Elevated Myocardial Infarction, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Observational StudyOther
This study does not involve any active intervention. It is an observational study comparing the outcomes of invasive and conservative treatment strategies for non-ST elevation myocardial infarction (NSTEMI) in cancer patients. The treatments are based on the clinical decisions made by the attending physicians
| Study group | Role | What they receive |
|---|---|---|
| Invasive Treatment Group | The Invasive Treatment Group will include cancer patients aged 18 and older diagnosed with non-ST elevation myocardial infarction (NSTEMI) who received an invasive treatment approach. This group will consist of patients who underwent coronary angiography followed by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). These patients may have various cancer types, with no restriction on the diagnosis, but must have been treated with invasive procedures for NSTEMI during their hospitalization. The cohort will be assessed for mortality, re-hospitalization rates, and cardiovascular events. The study will also evaluate factors such as cancer stage, metastasis, and comorbidities to understand the outcomes of invasive treatment in this population. Receives: Other: Observational Study | |
| Conservative Treatment Group | The Conservative Treatment Group will include cancer patients aged 18 and older diagnosed with NSTEMI and managed with medical treatment alone. This group will consist of patients who received pharmacological management (antiplatelet therapy, anticoagulants, beta-blockers, statins) without coronary angiography or revascularization. These patients may have different cancer types, and the study will focus on those treated conservatively during their hospital stay. Mortality, re-hospitalization, and cardiovascular events will be assessed. The analysis will also consider cancer type, disease stage, comorbidities, and pharmacological therapy's impact on long-term outcomes. Receives: Other: Observational Study |
What is being measured
The primary outcome is the main question the study is designed to answer.
hospital mortality
Hospital mortality rate in cancer patients with non-ST elevation myocardial infarction, comparing invasive and conservative treatment strategies
Measured: From the date of hospital admission for NSTEMI until the occurrence of mortality, cardiovascular events, or hospital discharge, assessed up to 30 days.
Secondary outcomes (2)
Length of hospital stay:
Comparison of the duration of hospitalization between the invasive treatment group and the conservative treatment group.
Measured: From the date of hospital admission for NSTEMI until the occurrence of mortality, cardiovascular events, or hospital discharge, assessed up to 100 days.
Re-hospitalization rate
Rate of readmission after initial discharge, comparing the two treatment strategies.
Measured: The time frame for assessing re-hospitalization is from the date of hospital discharge to 100 days post-discharge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Nov 2024
- Study start1 Jun 2024
- Primary completion20 Nov 2024
- Study completion1 Apr 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myocardial InfarctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 12,500 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Arif Timuroğlu, MD, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
- Investigators
- Arif Timuroğlu, Principal investigator, ankara oncology trainig and research hospitalİmran Ceren, Principal investigator, ankara oncology trainig and research hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06702436
- Sponsor's protocol ID
- NONST_MI_ONCOLOGY
- Acronym
- CAN-NSTEMI
- Status last verified
- Sep 2025
- First submitted
- 19 Nov 2024
- Last updated
- 16 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Treatment Approaches on Mortality in Cancer Patients With Non-ST Elevation Myocardial Infarction: Invasive vs. Conservative Strategies
- ClinicalTrials.gov ID
- NCT06702436
- Acronym / sponsor ID
- CAN-NSTEMI / NONST_MI_ONCOLOGY
- Conditions
- Myocardial Infarction
- Keywords
- Non-ST Elevated Myocardial Infarction, Malignancy, Mortality
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 12,500 participants (actual)
- Lead sponsor
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research HospitalUniversity, hospital or other
- Study start
- 1 Jun 2024 (actual)
- Primary completion
- 20 Nov 2024 (actual)
- Study completion
- 1 Apr 2025 (actual)
- First posted
- 25 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This retrospective study investigates the impact of invasive versus conservative management strategies in cancer patients presenting with non-ST elevation myocardial infarction (non-ST MI). Patients aged 18 and older, who were treated for non-ST MI in a hospital setting and had a confirmed cancer diagnosis, are included. The primary outcome is hospital mortality, assessed using GRACE scores to evaluate mortality risk. Patients are grouped based on their received interventions-either invasive (including coronary angiography and revascularization) or pharmacological treatment. Risk factors contributing to mortality, such as cancer type, metastasis presence, comorbidities, and laboratory findings, will also be analyzed to better understand the interplay of oncologic and cardiovascular conditions in this population.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Invasive Treatment Group | – | Other: Observational StudyThe Invasive Treatment Group will include cancer patients aged 18 and older diagnosed with non-ST elevation myocardial infarction (NSTEMI) who received an invasive treatment approach. This group will consist of patients who underwent coronary angiography followed by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). These patients may have various cancer types, with no restriction on the diagnosis, but must have been treated with invasive procedures for NSTEMI during their hospitalization. The cohort will be assessed for mortality, re-hospitalization rates, and cardiovascular events. The study will also evaluate factors such as cancer stage, metastasis, and comorbidities to understand the outcomes of invasive treatment in this population. |
| Conservative Treatment Group | – | Other: Observational StudyThe Conservative Treatment Group will include cancer patients aged 18 and older diagnosed with NSTEMI and managed with medical treatment alone. This group will consist of patients who received pharmacological management (antiplatelet therapy, anticoagulants, beta-blockers, statins) without coronary angiography or revascularization. These patients may have different cancer types, and the study will focus on those treated conservatively during their hospital stay. Mortality, re-hospitalization, and cardiovascular events will be assessed. The analysis will also consider cancer type, disease stage, comorbidities, and pharmacological therapy's impact on long-term outcomes. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will include adult patients aged 18 and older, diagnosed with cancer and hospitalized for non-ST elevation myocardial infarction (NSTEMI). Both males and females with various cancer types will be eligible, and the study will focus on those receiving either invasive or conservative treatment for NSTEMI. Patients with severe comorbidities, such as end-stage diseases or missing critical data, will be excluded. The study aims to assess the impact of invasive versus conservative treatment strategies on mortality, re-hospitalization, and cardiovascular events in this cohort, which is often underrepresented in clinical trials. This population will help understand optimal treatment approaches for cancer patients with NSTEMI.
Key inclusion criteria (5 listed)
- Age: Patients aged 18 years and older.
- Diagnosis: Patients with a confirmed cancer diagnosis.
- Acute Condition: Patients diagnosed with non-ST elevation myocardial infarction (non-ST MI).
- Treatment: Patients who received either invasive treatment (including coronary angiography and revascularization) or conservative (pharmacological) treatment for non-ST MI.
- Consent: Patients who have provided informed consent or are part of a retrospective study where consent is waived.
Key exclusion criteria (7 listed)
- Age: Patients younger than 18 years.
- Non-cancer diagnoses: Patients without a cancer diagnosis.
- ST-Elevation Myocardial Infarction: Patients with ST elevation myocardial infarction (STEMI) instead of non-ST elevation myocardial infarction (NSTEMI).
- Pre-existing severe comorbidities: Patients with severe or terminal comorbidities (e.g., end-stage liver disease, end-stage renal disease, or severe cognitive impairment) that would confound the outcomes.
- Incomplete medical records: Patients with missing data on relevant clinical variables (e.g., GRACE score, treatment received, or mortality data).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Observational StudyThis study does not involve any active intervention. It is an observational study comparing the outcomes of invasive and conservative treatment strategies for non-ST elevation myocardial infarction (NSTEMI) in cancer patients. The treatments are based on the clinical decisions made by the attending physicians | Other | Conservative Treatment Group, Invasive Treatment Group |
Primary outcome
hospital mortality
Time frame: From the date of hospital admission for NSTEMI until the occurrence of mortality, cardiovascular events, or hospital discharge, assessed up to 30 days.
Hospital mortality rate in cancer patients with non-ST elevation myocardial infarction, comparing invasive and conservative treatment strategies
2 secondary outcomes
Length of hospital stay:
Time frame: From the date of hospital admission for NSTEMI until the occurrence of mortality, cardiovascular events, or hospital discharge, assessed up to 100 days.
Re-hospitalization rate
Time frame: The time frame for assessing re-hospitalization is from the date of hospital discharge to 100 days post-discharge
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Myocardial Infarction
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
Enrolling by invitation
The DANE-HEART Trial - Computed Tomography Coronary Angiography for Primary Prevention
Coronary Atherosclerosis and Other Heart Disease, Cardiovascular Diseases
Not yet recruitingObservational study
Elicit Drugs in Myocardial Infarction
Young Patients With Acute Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Arif Timuroğlu principal investigator
ankara oncology trainig and research hospital
İmran Ceren principal investigator
ankara oncology trainig and research hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Myocardial Infarction, run by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
hospital mortality (time frame: From the date of hospital admission for NSTEMI until the occurrence of mortality, cardiovascular events, or hospital discharge, assessed up to 30 days.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2025.